Home > News > Dabur Pharma gets DCGI nod for Nanoxel
January 31st, 2008
Dabur Pharma gets DCGI nod for Nanoxel
Abstract:
Leading oncology player Dabur Pharma (Q, N,C,F)* said on Thursday that the Drug Controller General of India (DCGI) has approved its proprietary Nanoparticle Paclitaxel formulation `Nanoxel` for additional indications of ovarian cancer, non-small cell lung cancer and AIDS related Kaposis`s Sarcoma.
Nanoxel had earlier been approved by the DCGI in 2006 for the treatment of breast cancer and after its launch in Jan. 2007, hundreds of patients have benefited from this novel formulation.
Source:
myiris.com
Bookmark:
| Related News Press |
News and information
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Govt.-Legislation/Regulation/Funding/Policy
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Institute for Nanoscience hosts annual proposal planning meeting May 16th, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||